Eptifibatide
Eptifibatide is an inhibitor of glycoprotein GP IIb/IIIa that exhibits antiplatelet/antithrombotic activity. Eptifibatide inhibits fibrinogen-mediated platelet aggregation and is clinically used to treat acute coronary syndrome.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/1892020/
| Cas No. |
188627-80-7 |
|---|---|
| Purity |
≥98% |
| Formula |
C35H49N11O9S2 |
| Formula Wt. |
832.4 |
| Chemical Name |
N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophy-L-prolyl-L-Cysteinamide, cyclic (1-6)-disulfide |
| IUPAC Name |
2-[20-carbamoyl-12-[4-(diaminomethylideneamino)butyl]-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,22-hexaoxo-17,18-dithia-1,4,7,10,13,21-hexazabicyclo[21.3.0]hexacosan-6-yl]acetic acid |
| Synonym |
Integrilin |
| Appearance |
White to off white powder |
Angiolillo DJ. The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs. 2012 Nov 12;72(16):2087-116. PMID: 23083110.
Gurbel PA, Galbut B, Bliden KP, et al. Effect of eptifibatide for acute coronary syndromes: rapid versus late administration–therapeutic yield on platelets (The EARLY Platelet Substudy). J Thromb Thrombolysis. 2002 Dec;14(3):213-9. PMID: 12913401.
